Effects of Immulina Dietary Supplementation on Innate and Adaptive Immune Measures in Normal Human Volunteers

About this Study

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of oral Immulina supplementation on specific immune biomarkers in the blood.

Sponsor Protocol ID:2019-0183
IRB Number:2019-0183
Closed for Enrollment
Interventional
Early Phase 1
Eligibility Criteria
18 years old
64 years old
Both Male and Female
No
No
Yes

Inclusion CriteriaNormal, generally healthy adults between ages 18-64 and who may or may not have a controlled disease(s). Examples of controlled diseases are controlled Type-2 diabetes mellitus, controlled hypertension, controlled allergic rhinitis, etc

Exclusion Criteria

1.    Individuals with specific disease entities, which, in the opinion of the PI, could reasonably be assumed to have dysfunctional immune function as a component of their illness.  These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, Rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barre syndrome, psoriasis, Grave’s disease, Hashimoto’s thyroiditis, myasthenia gravis or vasculitis.

2.    Individuals taking  specific dietary supplements including probiotics, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.).  If the potential participant reports usage of any of these products, they will be asked if they would be willing to withhold products for 30 days and then be re-screened for inclusion/exclusion criteria.

3.    Individuals who are unwilling to refrain for the duration of the study from taking the specific dietary supplements and fermented food products listed in exclusion criteria #2

4.    Pregnant females (because baseline immune responses are altered by pregnancy)

5.    Individuals unable to speak, understand and read English

Categories Click category to view its trials.
Allergy/Asthma/Immunology
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Angelena Sharp
Phone Number: 601-815-9282
Email: asharp@umc.edu
Principal Investigator:Marshall, Gailen D, M.D., Ph.D.
How to participate in our Clinical Trials